Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Best Practices" for FDA Advisory Committees

This article was originally published in RPM Report

Executive Summary

The Food & Drug Administration has wrapped up an extensive review of the advisory committee process with a plan to implement "best practices" across its system of outside expert panels. The changes, which were announced as part of FDA's response to the Institute of Medicine report on drug safety, include three guidances slated for release in 2007.

You may also be interested in...



Reconstructing Advisory Committees: FDA Conflict of Interest Policy Will Pose Challenges for Drug Sponsors

Drug sponsors soon will have another hurdle to overcome at advisory committee meetings: significant turnover in the experts asked to consider the approvability of their products. The new policy will help FDA quiet critics of the agency's advisory committee system, but it will also create more noise around the drug approval process.

FDA's Selective Response to the IoM Drug Safety Report

FDA says its plan to improve the post-marketing drug safety system embraces most of the recommendations made by the Institute of Medicine in a 2006 report. But in several respects, the agency's response isn't exactly what IoM had in mind.

FDA's Selective Response to the IoM Drug Safety Report

FDA says its plan to improve the post-marketing drug safety system embraces most of the recommendations made by the Institute of Medicine in a 2006 report. But in several respects, the agency's response isn't exactly what IoM had in mind.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel